PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

Abstract

BackgroundAnti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) agents are broadly used in first-line and second-line treatment across different tumor types. While immunohistochemistry-based assays are routinely...